Arvinas, Inc. (ARVN)
NASDAQ: ARVN · Real-Time Price · USD
8.03
-0.02 (-0.25%)
At close: Jun 25, 2026, 4:00 PM EDT
8.02
-0.01 (-0.12%)
Pre-market: Jun 26, 2026, 8:57 AM EDT
Arvinas Employees
Arvinas had 246 employees as of December 31, 2025. The number of employees decreased by 184 or -42.79% compared to the previous year.
Employees
246
Change (1Y)
-184
Growth (1Y)
-42.79%
Revenue / Employee
$363,415
Profits / Employee
-$899,593
Market Cap
518.11M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 246 | -184 | -42.79% |
| Dec 31, 2024 | 430 | -15 | -3.37% |
| Dec 31, 2023 | 445 | 30 | 7.23% |
| Dec 31, 2022 | 415 | 135 | 48.21% |
| Dec 31, 2021 | 280 | 101 | 56.42% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Valneva SE | 674 |
| REGENXBIO | 371 |
| ProKidney | 231 |
| Kyverna Therapeutics | 130 |
| Assembly Biosciences | 73 |
| Rezolute | 68 |
| Prothena Corporation | 67 |
| Achieve Life Sciences | 28 |
ARVN News
- 2 days ago - Arvinas Transcript: AGM 2026 - Transcripts
- 22 days ago - Arvinas Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 27 days ago - Arvinas to Present at Jefferies Global Healthcare Conference - GlobeNewsWire
- 5 weeks ago - Arvinas Employees Give Back During Company-wide Impact Day - GlobeNewsWire
- 6 weeks ago - Arvinas price target raised to $16 from $14 at BofA - TheFly
- 6 weeks ago - Arvinas price target raised to $18 from $16 at BTIG - TheFly
- 6 weeks ago - Arvinas price target raised to $20 from $18 at Barclays - TheFly
- 6 weeks ago - H.C. Wainwright says Pfizer handing off Veppanu to Rigel ‘makes strategic sense’ - TheFly